# A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

> **NCT01071954** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 66 (actual)

## Conditions studied

- Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

## Interventions

- **BIOLOGICAL:** Romiplostim

## Key facts

- **NCT ID:** NCT01071954
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-30
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071954, "A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01071954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*